Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells (scientific article published on 27 February 2020)

Syntenin regulates TGF-β1-induced Smad activation and the epithelial-to-mesenchymal transition by inhibiting caveolin-mediated TGF-β type I receptor internalization

Q28118751

The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression

Q28595042

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

Q29614278

Molecular requirements for epithelial-mesenchymal transition during tumor progression

Q29618960

Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2

Q33686871

The molecular biology of chronic myeloid leukemia.

Q34079452

Specific targeted therapy of chronic myelogenous leukemia with imatinib

Q34215244

Monitoring response and resistance to treatment in chronic myeloid leukemia

Q34761663

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back

Q35128883

Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells

Q35814987

Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation

Q36130255

The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy.

Q36182260

Genetic and epigenetic regulators of pluripotency

Q36744480

Epigenetic reprogramming and induced pluripotency

Q37201452

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

Q37283128

The Culture-Repopulating Ability assays and incubation in low oxygen: a simple way to test drugs on leukaemia stem or progenitor cells.

Q37290636

Wnt signaling in hematopoiesis: crucial factors for self-renewal, proliferation, and cell fate decisions

Q37673086

Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia.

Q51181111

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.

Q51371803

Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion.

Q52552851

Human leukemia K-562 cells: induction of erythroid differentiation by 5-azacytidine

Q61890299

Terminal erythroid differentiation in the K-562 cell line by 1-beta-D-arabinofuranosylcytosine: accompaniment by c-myc messenger RNA decrease

Q61897325

Flow cytometric analysis of the phenotypic changes in tumour cell lines following TPA induction

Q68465559

Megakaryoblastic differentiation of proerythroblastic K562 cell-line cells

Q72813175

The effects of growth factors on multicellular spheroids formed by chick embryonic retinal cells

Q73851749

Nilotinib

Q81561753

Hybrid epithelial/mesenchymal phenotype(s): The 'fittest' for metastasis?

Q89573631

Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications

Q37735627

CD44 in hematological neoplasias

Q37831812

Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.

Q38260649

The chronic myeloid leukemia stem cell: stemming the tide of persistence

Q38761787

Decreased Expression of Caveolin-1 and E-Cadherin Correlates with the Clinicopathologic Features of Gastric Cancer and the EMT Process

Q38799102

CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition

Q38980899

Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties

Q39117436

Epithelial-to-mesenchymal transition in tumor progression

Q39339887

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.

Q39370827

Targeting of CD44 eradicates human acute myeloid leukemic stem cells

Q40228130

Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells

Q40228137

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Q40302552

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

Q41356541

Induction of erythroid differentiation in the human leukaemia cell line K562.

Q43585129

Erythroid differentiation and modulation of c-myc expression induced by antineoplastic drugs in the human leukemic cell line K562.

Q44370532

Fibroblast growth factor-2 in serum-free medium is a potent mitogen and reduces dedifferentiation of human ear chondrocytes in monolayer culture.

Q45008815

Fully Dedifferentiated Chondrocytes Expanded in Specific Mesenchymal Stem Cell Growth Medium with FGF2 Obtains Mesenchymal Stem Cell Phenotype In Vitro but Retains Chondrocyte Phenotype In Vivo

Q49478142

E-cadherin: Its dysregulation in carcinogenesis and clinical implications.

Q49570064

Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring.

Q49984629

P275

Creative Commons Attribution 4.0 International

copyrighted